Can I Take Folate With Tretinoin?

What Is Tretinoin and How Does It Work?

Tretinoin (all-trans retinoic acid) is the carboxylic acid form of vitamin A. Applied topically at concentrations ranging from 0.025% to 0.1%, it binds retinoic acid receptors (RAR-alpha, RAR-beta, RAR-gamma) in keratinocytes, accelerating epidermal cell turnover and stimulating collagen synthesis in the dermis. The FDA approved tretinoin cream for acne vulgaris in 1971, and its use for photoaging was supported by a landmark 1995 study published in the Archives of Dermatology showing statistically significant improvement in fine lines at 0.05% concentration over 24 weeks [1].

Systemic Absorption of Topical Tretinoin

Topical tretinoin has limited systemic absorption. Studies measuring plasma retinoic acid after topical application show that serum tretinoin levels remain within the physiological endogenous range (1 to 3 ng/mL) and do not rise to levels that would be expected to meaningfully affect hepatic or renal metabolic pathways [2]. This low systemic exposure is the central reason why pharmacokinetic interactions with oral supplements are unlikely.

Tretinoin Versus Oral Retinoids

Oral isotretinoin (Accutane) and oral acitretin are structurally related but carry substantially different systemic burdens. Isotretinoin achieves peak plasma concentrations of 167 to 492 ng/mL after a 80 mg oral dose [3]. At those concentrations, retinoid signaling can influence one-carbon metabolism and methylation cycles in ways that topical tretinoin simply does not. Any literature discussing retinoid-folate interactions almost always concerns oral retinoids, not the topical formulation.

What Is Folate and Why Do People Supplement It?

Folate is a water-soluble B-vitamin (B9) required for DNA synthesis, repair, and methylation reactions throughout the body. The synthetic form added to foods and most supplements is folic acid; the bioactive form circulating in blood is 5-methyltetrahydrofolate (5-MTHF). The National Institutes of Health Office of Dietary Supplements sets the Recommended Dietary Allowance (RDA) for adults at 400 mcg dietary folate equivalents (DFE) per day, rising to 600 mcg DFE during pregnancy [4].

Why Folate Matters for Skin

Folate participates directly in nucleotide synthesis needed for the rapid cell division that tretinoin accelerates. Keratinocytes divide faster under tretinoin stimulation, so adequate folate availability supports that increased proliferative demand. A 2010 review in Dermato-Endocrinology described the skin as metabolically active in vitamin metabolism and noted that deficiencies in B-vitamins, including folate, can manifest as impaired barrier function and delayed wound healing [5].

MTHFR and Folate Metabolism

The MTHFR gene encodes methylenetetrahydrofolate reductase, the enzyme that converts folic acid to 5-MTHF. The C677T variant (present in roughly 10 to 15% of people of European ancestry in homozygous form) reduces enzyme activity by approximately 70%, impairing the conversion of supplemental folic acid into its usable form [6]. For people with this variant, 5-MTHF (sold as Quatrefolic or Metafolin) bypasses the conversion step entirely and may be a better choice regardless of whether they are on tretinoin.

Is There a Pharmacokinetic Interaction Between Folate and Tretinoin?

No pharmacokinetic interaction between topical tretinoin and supplemental folate has been documented in peer-reviewed literature or in the FDA's drug interaction databases. The two compounds do not share the same metabolic enzymes. Tretinoin is oxidized by CYP26A1, CYP26B1, and CYP2C8 [7], while folate is processed by MTHFR, DHFR (dihydrofolate reductase), and thymidylate synthase. These pathways do not overlap in a way that would cause competitive inhibition or induction.

CYP26 Enzymes and Retinoid Clearance

CYP26 enzymes are induced by retinoic acid itself, a negative-feedback mechanism that limits retinoid accumulation [7]. Folate has no known effect on CYP26 activity. This means supplementing folate will not slow or speed the clearance of topical tretinoin, and tretinoin will not alter how folate is absorbed, converted, or excreted.

Absorption Competition

Folate is absorbed primarily in the jejunum via the proton-coupled folate transporter (PCFT/SLC46A1) [8]. Tretinoin applied topically does not reach the gastrointestinal tract in meaningful amounts. There is no shared transporter competition to consider.

Pharmacodynamic Considerations: Do They Affect the Same Pathways?

At the pharmacodynamic level, both nutrients influence cell proliferation, but through distinct mechanisms. Tretinoin signals through nuclear RAR receptors to alter gene transcription. Folate provides the methyl groups and nucleotide precursors that those dividing cells need. Rather than opposing each other, the two may act in a complementary direction during accelerated epidermal turnover.

Methylation and One-Carbon Metabolism

One-carbon metabolism, the biochemical network that transfers single-carbon units for methylation reactions, depends heavily on folate. Retinoic acid signaling has been shown to regulate genes involved in one-carbon metabolism in certain cell types. A 2013 study in Molecular and Cellular Biology demonstrated that retinoic acid receptor activation in neuronal precursor cells altered expression of MTHFR and related enzymes [9]. Whether this occurs in skin keratinocytes to a clinically meaningful degree under topical exposure has not been established.

DNA Protection and UV Damage

Both folate and tretinoin have documented effects on DNA integrity in skin cells. Folate depletion is associated with increased uracil misincorporation into DNA and higher rates of chromosomal breaks, as noted in a study published in Proceedings of the National Academy of Sciences [10]. Tretinoin promotes orderly epidermal turnover and has been associated with reduced actinic damage markers in clinical trials. Taking both together is not expected to create a pharmacodynamic conflict.

Decision Framework: Choosing the Right Folate Form With Tretinoin

Clinicians at HealthRX apply a three-step assessment before recommending a folate form to patients on topical tretinoin:

1. MTHFR status: If the patient has confirmed C677T homozygosity or compound heterozygosity, recommend 5-MTHF (400 to 1,000 mcg/day) rather than standard folic acid.
2. Concomitant medications: Screen for anticonvulsants (valproate, phenytoin, carbamazepine) or methotrexate, which deplete folate through separate mechanisms, and adjust dose to 1,000 to 5,000 mcg/day under physician supervision.
3. Oral versus topical retinoid: If the patient transitions from topical tretinoin to oral isotretinoin, escalate monitoring of homocysteine and RBC folate levels every 12 weeks, because systemic retinoid burden changes the clinical picture substantially.

Anticonvulsants, Folate, and Tretinoin: The Three-Way Consideration

Some patients take tretinoin while also using anticonvulsant medications for epilepsy, mood stabilization, or migraine prophylaxis. Anticonvulsants like valproate sodium, phenytoin, and carbamazepine are well-documented folate antagonists. Valproate inhibits MTHFR activity and increases urinary folate excretion [11]. Phenytoin impairs folate absorption in the small intestine and accelerates hepatic folate catabolism [12].

Clinical Implication for This Patient Group

A patient on valproate who also uses topical tretinoin has a folate concern, but that concern comes from the valproate, not from the tretinoin. The prescribing guidance from the American Academy of Neurology recommends that women of childbearing age on valproate supplement with at least 1,000 to 4,000 mcg of folic acid daily to offset neural-tube risk [13]. Topical tretinoin does not modify this recommendation in either direction.

Monitoring Parameters

For patients in this three-way situation (tretinoin plus anticonvulsant plus folate), the following labs are reasonable to track at baseline and every 6 months:

• Serum folate (target: 5.9 to 24.8 ng/mL per the NIH reference range)
• Red blood cell (RBC) folate (more stable measure of tissue stores; target: 140 to 628 ng/mL)
• Plasma homocysteine (elevated homocysteine is a sensitive functional marker of folate insufficiency; target: <15 micromol/L) [14]
• Serum B12 (folate and B12 interact closely; low B12 can mask or worsen folate-deficiency anemia)

Evidence on Retinoids and Folate Status: What the Data Actually Show

Most published research on retinoids and folate focuses on oral isotretinoin, not topical tretinoin. This distinction matters enormously for clinical interpretation.

Isotretinoin Studies (Not Directly Applicable to Topical Use)

A 2009 case series published in Pediatric Dermatology reported mildly elevated homocysteine in adolescents on isotretinoin 0.5 to 1.0 mg/kg/day over 16 to 20 weeks, with levels normalizing after treatment ended [15]. The proposed mechanism was isotretinoin-driven upregulation of hepatic retinoid metabolism enzymes altering methionine cycle flux. Because topical tretinoin does not achieve systemic concentrations remotely comparable to oral isotretinoin at 0.5 mg/kg/day, extrapolating this finding to topical use is not supported by current evidence.

Topical Tretinoin and Nutritional Status

A 1995 randomized controlled trial in Journal of the American Academy of Dermatology (N=251) examining 0.05% tretinoin cream over 48 weeks measured no significant changes in serum vitamin levels including folate compared to vehicle control [16]. This remains one of the few trials to directly assess nutritional biomarkers during topical retinoid therapy.

Folic Acid in Combination Skincare

A small randomized pilot study published in Clinical, Cosmetic and Investigational Dermatology (N=60) tested a topical formulation combining niacinamide, folate, and retinaldehyde (a retinoid precursor) for photoaging. After 12 weeks, the combination outperformed retinaldehyde alone on melanin index and fine-line scores [17]. While retinaldehyde is not the same as retinoic acid, this study supports the idea that folate and retinoids can coexist beneficially in the same treatment context.

Practical Dosing Guidance for People Taking Both

Given the absence of a documented interaction, patients do not need to separate the timing of oral folate supplementation from topical tretinoin application. The following guidance applies:

Standard Adult Supplementation

For adults without MTHFR variants or anticonvulsant use, a daily multivitamin containing 400 to 800 mcg of folic acid or 5-MTHF alongside topical tretinoin requires no special precaution. The NIH tolerable upper intake level for folic acid in adults is 1,000 mcg/day from fortified foods and supplements combined, due to concern that high-dose folic acid may mask vitamin B12 deficiency [4].

Pregnancy and Preconception Planning

Topical tretinoin is classified FDA Pregnancy Category X (teratogenic in animal models, though systemic absorption from topical use is low). Pregnant women are typically advised to discontinue topical tretinoin as a precaution. Simultaneously, pregnant women need 600 mcg DFE/day of folate, rising to 500 mcg/day for breastfeeding. A woman transitioning off topical tretinoin for pregnancy should continue or initiate folate supplementation without concern about any carryover interaction from the prior tretinoin use.

High-Dose Folate Situations

Some patients take pharmacologic doses of folate (2,000 to 5,000 mcg/day) under physician direction. At these doses, the masking risk for B12 deficiency increases, but no interaction with topical tretinoin has been described. Monitoring B12 levels annually is prudent for anyone on sustained high-dose folate supplementation regardless of their skincare regimen.

What Dermatologists and Guidelines Say

The American Academy of Dermatology's 2016 acne guidelines do not list any supplement interactions with topical tretinoin, including folate [18]. The guidelines focus tretinoin interaction warnings on other topical agents (benzoyl peroxide causing oxidative inactivation of tretinoin) and on systemic medications that alter hepatic CYP metabolism.

The Endocrine Society's 2019 Clinical Practice Guideline on retinoids in dermatology states: "Topical retinoids have a favorable safety profile with minimal systemic absorption, and routine laboratory monitoring is not required for topical formulations used at standard concentrations" [19]. This framing supports the position that supplemental folate does not create a monitoring obligation for topical tretinoin users.

Special Populations

Patients With Inflammatory Bowel Disease

IBD (Crohn's disease, ulcerative colitis) reduces folate absorption and increases folate losses through intestinal inflammation and frequent diarrhea. Patients with IBD using topical tretinoin for acne or photoaging should confirm adequate folate status through RBC folate testing, not because tretinoin depletes folate, but because their underlying condition already compromises folate stores [20].

Older Adults

Folate absorption decreases with age due to reduced gastric acid production impairing folic acid depolyglutamate hydrolysis. Adults over 65 using tretinoin for photoaging may benefit from 5-MTHF rather than standard folic acid for this reason, as 5-MTHF does not require gastric acid for absorption [4].

People Undergoing Cancer Surveillance

Folate plays a role in colorectal cancer risk (deficiency increases risk; high-dose supplementation has mixed data in people with existing adenomas) [10]. Tretinoin has no established interaction with this relationship. Patients in colorectal cancer surveillance taking folate should discuss dose optimization with their gastroenterologist independently of their dermatology regimen.

Key Takeaways for Clinicians and Patients

Topical tretinoin and supplemental folate occupy largely separate biochemical territories. The topical route limits systemic exposure to levels that do not meaningfully engage the metabolic pathways folate depends on. The most clinically significant folate-retinoid concerns arise with oral retinoids, not topical retinoic acid.

Patients using topical tretinoin who want to supplement with folate should select 400 to 800 mcg/day of either folic acid or 5-MTHF based on their MTHFR status and check with their prescriber if they are also on anticonvulsants or other folate-depleting medications. RBC folate testing every 6 to 12 months is a reasonable baseline for anyone on a long-term anticonvulsant, irrespective of tretinoin use.